O	0	10	Randomized
O	11	17	double
O	17	18	-
O	18	23	blind
O	24	31	placebo
O	31	32	-
O	32	42	controlled
O	43	48	trial
O	49	51	of
B-intervention	52	58	acetyl
I-intervention	58	59	-
I-intervention	59	60	L
I-intervention	60	61	-
I-intervention	61	70	carnitine
O	71	74	for
O	75	78	the
O	79	89	prevention
O	90	92	of
B-condition	93	99	taxane
I-condition	99	100	-
I-condition	100	107	induced
I-condition	108	118	neuropathy
O	119	121	in
B-eligibility	122	127	women
I-eligibility	128	138	undergoing
I-eligibility	139	147	adjuvant
I-eligibility	148	154	breast
I-eligibility	155	161	cancer
I-eligibility	162	169	therapy
O	169	170	.

O	171	183	Chemotherapy
O	183	184	-
O	184	191	induced
O	192	202	peripheral
O	203	213	neuropathy
O	214	215	(
O	215	219	CIPN
O	219	220	)
O	221	223	is
O	224	230	common
O	231	234	and
O	235	240	leads
O	241	243	to
O	244	254	suboptimal
O	255	264	treatment
O	264	265	.

O	266	272	Acetyl
O	272	273	-
O	273	274	L
O	274	275	-
O	275	284	carnitine
O	285	286	(
O	286	289	ALC
O	289	290	)
O	291	293	is
O	294	295	a
O	296	303	natural
O	304	312	compound
O	313	321	involved
O	322	324	in
O	325	333	neuronal
O	334	344	protection
O	344	345	.

O	346	353	Studies
O	354	358	have
O	359	368	suggested
O	369	372	ALC
O	373	376	may
O	377	379	be
O	380	389	effective
O	390	393	for
O	394	397	the
O	398	408	prevention
O	409	412	and
O	413	422	treatment
O	423	425	of
O	426	430	CIPN
O	430	431	.

O	432	433	A
O	434	436	24
O	436	437	-
O	437	441	week
O	442	452	randomized
O	453	459	double
O	459	460	-
O	460	465	blind
O	466	471	trial
O	472	481	comparing
O	482	485	ALC
O	486	487	(
O	487	488	3
O	488	489	,
O	489	492	000
O	493	495	mg
O	496	499	per
O	500	503	day
O	503	504	)
O	505	509	with
B-control	510	517	placebo
O	518	520	in
O	521	526	women
O	527	537	undergoing
O	538	546	adjuvant
O	547	553	taxane
O	553	554	-
O	554	559	based
O	560	572	chemotherapy
O	573	576	was
O	577	586	conducted
O	586	587	.

O	588	591	The
O	592	599	primary
O	600	609	objective
O	610	613	was
O	614	616	to
B-outcome-Measure	617	626	determine
I-outcome-Measure	627	629	if
I-outcome-Measure	630	633	ALC
I-outcome-Measure	634	642	prevents
I-outcome-Measure	643	647	CIPN
O	648	650	as
O	651	659	measured
O	660	662	by
O	663	666	the
O	667	669	11
O	669	670	-
O	670	674	item
O	675	688	neurotoxicity
O	689	690	(
O	690	693	NTX
O	693	694	)
O	695	704	component
O	705	707	of
O	708	711	the
O	712	722	Functional
O	723	733	Assessment
O	734	736	of
O	737	743	Cancer
O	744	751	Therapy
O	752	753	(
O	753	757	FACT
O	757	758	)
O	759	760	-
O	760	766	Taxane
O	767	772	scale
O	773	775	at
O	776	778	12
O	779	784	weeks
O	784	785	.

O	786	795	Secondary
O	796	806	objectives
O	807	815	included
B-outcome-Measure	816	823	changes
I-outcome-Measure	824	826	in
I-outcome-Measure	827	829	24
I-outcome-Measure	829	830	-
I-outcome-Measure	830	834	week
I-outcome-Measure	835	838	end
I-outcome-Measure	839	845	points
O	845	846	,
B-outcome-Measure	847	857	functional
I-outcome-Measure	858	864	status
O	865	866	(
O	866	870	FACT
O	870	871	-
O	871	876	Trial
O	877	884	Outcome
O	885	890	Index
O	891	892	[
O	892	895	TOI
O	895	896	]
O	896	897	)
O	897	898	,
B-outcome-Measure	899	906	fatigue
O	907	908	(
O	908	918	Functional
O	919	929	Assessment
O	930	932	of
O	933	940	Chronic
O	941	948	Illness
O	949	956	Therapy
O	957	958	[
O	958	963	FACIT
O	963	964	]
O	965	966	-
O	966	973	Fatigue
O	973	974	)
O	974	975	,
O	976	979	and
B-outcome-Measure	980	983	NTX
I-outcome-Measure	984	989	grade
O	989	990	.

O	991	992	A
O	993	998	total
O	999	1001	of
B-total-participants	1002	1005	409
O	1006	1014	patients
O	1015	1019	were
O	1020	1029	evaluable
O	1030	1031	(
B-intervention-participants	1031	1034	208
O	1035	1043	received
O	1044	1047	ALC
O	1047	1048	;
B-control-participants	1049	1052	201
O	1052	1053	,
O	1054	1061	placebo
O	1061	1062	)
O	1062	1063	.

O	1064	1066	In
O	1067	1068	a
O	1069	1081	multivariate
O	1082	1088	linear
O	1089	1099	regression
O	1099	1100	,
O	1101	1105	week
O	1105	1106	-
O	1106	1108	12
O	1109	1115	scores
O	1116	1120	were
O	1121	1122	0
O	1122	1123	.
O	1123	1124	9
O	1125	1131	points
O	1132	1137	lower
O	1138	1139	(
O	1139	1143	more
O	1144	1148	CIPN
O	1148	1149	)
O	1150	1154	with
O	1155	1158	ALC
O	1159	1163	than
O	1164	1171	placebo
O	1172	1173	(
O	1173	1175	95
O	1175	1176	%
O	1177	1179	CI
O	1179	1180	,
O	1181	1182	-
O	1182	1183	2
O	1183	1184	.
O	1184	1185	2
O	1186	1188	to
O	1189	1190	0
O	1190	1191	.
O	1191	1192	4
O	1192	1193	;
O	1194	1195	P
O	1196	1197	=
O	1198	1199	.
O	1199	1201	17
O	1201	1202	)
O	1202	1203	,
O	1204	1211	whereas
O	1212	1216	week
O	1216	1217	-
O	1217	1219	24
O	1220	1226	scores
O	1227	1231	were
O	1232	1233	1
O	1233	1234	.
O	1234	1235	8
O	1236	1242	points
O	1243	1248	lower
O	1249	1253	with
O	1254	1257	ALC
O	1258	1259	(
O	1259	1261	95
O	1261	1262	%
O	1263	1265	CI
O	1265	1266	,
O	1267	1268	-
O	1268	1269	3
O	1269	1270	.
O	1270	1271	2
O	1272	1274	to
O	1275	1276	-
O	1276	1277	0
O	1277	1278	.
O	1278	1279	4
O	1279	1280	;
O	1281	1282	P
O	1283	1284	=
O	1285	1286	.
O	1286	1288	01
O	1288	1289	)
O	1289	1290	.

O	1291	1299	Patients
O	1300	1309	receiving
O	1310	1313	ALC
O	1314	1318	were
O	1319	1323	more
O	1324	1330	likely
O	1331	1333	to
O	1334	1338	have
O	1339	1340	a
B-outcome	1341	1342	>
I-outcome	1343	1344	5
I-outcome	1344	1345	-
I-outcome	1345	1350	point
I-outcome	1351	1359	decrease
I-outcome	1360	1362	in
I-outcome	1363	1367	FACT
I-outcome	1367	1368	-
I-outcome	1368	1371	NTX
I-outcome	1372	1378	scores
O	1379	1380	(
B-iv-bin-percent	1380	1382	38
I-iv-bin-percent	1382	1383	%
O	1384	1385	v
B-cv-bin-percent	1386	1388	28
I-cv-bin-percent	1388	1389	%
O	1389	1390	;
O	1391	1392	P
O	1393	1394	=
O	1395	1396	.
O	1396	1398	05
O	1398	1399	)
O	1399	1400	,
O	1401	1404	and
O	1405	1409	FACT
O	1409	1410	-
O	1410	1413	TOI
O	1414	1420	scores
O	1421	1425	were
O	1426	1427	3
O	1427	1428	.
O	1428	1429	5
O	1430	1436	points
O	1437	1442	lower
O	1443	1447	with
O	1448	1451	ALC
O	1452	1453	(
O	1453	1454	P
O	1455	1456	=
O	1457	1458	.
O	1458	1460	03
O	1460	1461	)
O	1461	1462	.

B-outcome	1463	1468	Grade
I-outcome	1469	1470	3
I-outcome	1471	1473	to
I-outcome	1474	1475	4
I-outcome	1476	1489	neurotoxicity
O	1490	1493	was
O	1494	1498	more
O	1499	1507	frequent
O	1508	1510	in
O	1511	1514	the
O	1515	1518	ALC
O	1519	1522	arm
O	1523	1524	(
B-iv-bin-abs	1524	1529	eight
O	1530	1531	v
B-cv-bin-abs	1532	1535	one
O	1535	1536	)
O	1536	1537	.

O	1538	1540	No
O	1541	1552	differences
O	1553	1560	between
O	1561	1565	arms
O	1566	1570	were
O	1571	1579	observed
O	1580	1583	for
B-outcome	1584	1589	FACIT
I-outcome	1589	1590	-
I-outcome	1590	1597	Fatigue
I-outcome	1598	1600	or
I-outcome	1601	1606	other
I-outcome	1607	1617	toxicities
O	1617	1618	.

B-outcome	1619	1624	Serum
I-outcome	1625	1634	carnitine
I-outcome	1635	1640	level
O	1641	1650	increased
O	1651	1655	with
O	1656	1659	ALC
O	1660	1663	but
O	1664	1672	remained
O	1673	1679	stable
O	1680	1684	with
O	1685	1692	placebo
O	1692	1693	.

O	1694	1699	There
O	1700	1703	was
O	1704	1706	no
O	1707	1715	evidence
O	1716	1720	that
O	1721	1724	ALC
O	1725	1733	affected
O	1734	1738	CIPN
O	1739	1741	at
O	1742	1744	12
O	1745	1750	weeks
O	1750	1751	;
O	1752	1759	however
O	1759	1760	,
O	1761	1764	ALC
O	1765	1778	significantly
O	1779	1788	increased
O	1789	1793	CIPN
O	1794	1796	by
O	1797	1799	24
O	1800	1805	weeks
O	1805	1806	.

O	1807	1811	This
O	1812	1814	is
O	1815	1818	the
O	1819	1824	first
O	1825	1830	study
O	1831	1833	to
O	1834	1837	our
O	1838	1847	knowledge
O	1848	1855	showing
O	1856	1860	that
O	1861	1862	a
O	1863	1874	nutritional
O	1875	1885	supplement
O	1886	1895	increased
O	1896	1900	CIPN
O	1900	1901	.

O	1902	1910	Patients
O	1911	1917	should
O	1918	1920	be
O	1921	1932	discouraged
O	1933	1937	from
O	1938	1943	using
O	1944	1955	supplements
O	1956	1963	without
O	1964	1970	proven
O	1971	1979	efficacy
O	1979	1980	.
